1-(Isopropylamino)-3-(p-[beta-methoxyethyl]phenoxy)-2-propanol tartrate

Base Information

• Chemical Name: 1-(Isopropylamino)-3-(p-[beta-methoxyethyl]phenoxy)-2-propanol tartrate
• CAS No.: 56392-17-7
• Molecular Formula: 2(C15H25NO3)^.(C4H6O6)
• Molecular Weight: 684.825
• Hs Code.: 29225090
• European Community (EC) Number: 260-148-9
• NCI Thesaurus Code: C29255
• RXCUI: 203191
• Mol file: 56392-17-7.mol

Synonyms:Beloc Duriles;Beloc-Duriles;Betaloc;Betaloc Astra;Betaloc-Astra;Betalok;CGP 2175;CGP-2175;CGP2175;H 93 26;H 93-26;H 9326;Lopressor;Metoprolol;Metoprolol CR XL;metoprolol CR-XL;metoprolol succinate;Metoprolol Tartrate;Seloken;Spesicor;Spesikor;Toprol;Toprol XL;Toprol-XL

Chemical Property of 1-(Isopropylamino)-3-(p-[beta-methoxyethyl]phenoxy)-2-propanol tartrate

Chemical Property:

• Appearance/Colour: crystalline powder
• Melting Point: 120oC
• Refractive Index: 1.5300 (estimate)
• Boiling Point: 398.6 °C at 760 mmHg
• Flash Point: 194.9 °C
• PSA: 216.50000
• Density: 1.1946 (rough estimate)
• LogP: 1.88560
• Storage Temp.: Desiccate at RT
• Solubility.: H2O: soluble50mg/mL
• Water Solubility.: Soluble in water (>1000 mg/ml), methanol (>500 mg/ml), chloroform (496 mg/ml), ethanol (31 mg/ml at 25°C), and DMSO (100 mg/ml at 25°C).
• Hydrogen Bond Donor Count: 8
• Hydrogen Bond Acceptor Count: 14
• Rotatable Bond Count: 21
• Exact Mass: 684.38332523
• Heavy Atom Count: 48
• Complexity: 349

Purity/Quality:

99% ^*data from raw suppliers

Metoprolol tartrate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): F,T
• Hazard Codes: F,T
• Statements: 11-23/24/25-39/23/24/25
• Safety Statements: 7-16-36/37-45-24/25

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(C(C(=O)O)O)(C(=O)O)O
• Isomeric SMILES: CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O
• Recent ClinicalTrials: Metoprolol to Reduce Perioperative Myocardial Injury
• Recent EU Clinical Trials: Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Distress Syndrome (ARDS)
• Uses: Hypertensive medication. A ? selective aryloxypropanolamine andrenergic antagonist. Used in the treatment of a variety of cardiovascular disorder. Antihypertensive; antianginal; antiarrhythmic (class II) A β1 selective aryloxypropanolamine andrenergic antagonist. Used in the treatment of a variety of cardiovascular disorder. Antihypertensive; antianginal; antiarrhythmic (class II). alpha(1)-adrenergic blocker A b1-Adrenergic blocker Metoprolol tartrate is an antagonist of the β1-AR (β1-adrenoceptor). It inhibits spontaneous endothelin-1 production in vitro and displays antihypertensive and antianginal activity in vivo.
• Description: Metoprolol (tartrate) (Item No. 21165) is an analytical reference standard categorized as a β1-adrenergic receptor blocker. This product is intended for use in analytical forensic applications. Metoprolol (succinate) is available as a general research tool .
• Therapeutic Function: Beta-adrenergic blocker
• Clinical Use: Beta-adrenoceptor blocker: Hypertension Angina Cardiac arrhythmias Migraine prophylaxis Hyperthyroidism
• Drug interactions: Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: NSAIDs antagonise hypotensive effect. Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide; concentration increased by propafenone and dronedarone. Antibacterials: concentration reduced by rifampicin. Antidepressants: enhanced hypotensive effect with MAOIs; concentration increased by citalopram and escitalopram and possibly by paroxetine - avoid. Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin. Antimalarials: increased risk of bradycardia with mefloquine; avoid with artemether/lumefantrine. Antipsychotics enhanced hypotensive effect with phenothiazines. Antivirals: avoid concomitant use with tipranavir in heart failure. Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil. Cytotoxics: possible increased risk of bradycardia with crizotinib. Diuretics: enhanced hypotensive effect. Fingolimod: possibly increased risk of bradycardia. Moxisylyte: possible severe postural hypotension.

Technology Process of 1-(Isopropylamino)-3-(p-[beta-methoxyethyl]phenoxy)-2-propanol tartrate

There total 4 articles about 1-(Isopropylamino)-3-(p-[beta-methoxyethyl]phenoxy)-2-propanol tartrate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 72.0%

(RS)-metoprolol (51384-51-1,37350-58-6) + tartaric acid (87-69-4,138508-61-9) → metoprolol tartrate (56392-17-7,74220-04-5,80416-08-6,80551-63-9,126794-42-1,129947-83-7,131478-70-1,148507-72-6,148507-73-7)

Guidance literature:

In acetone; for 4h; pH=6.2; Heating / reflux;

Reference yield:

→ metoprolol tartrate (56392-17-7,55250-54-9,60168-92-5,71307-49-8)

Guidance literature:

Reference yield:

4-(2-methoxyethyl)phenol (56718-71-9) → metoprolol tartrate (56392-17-7,74220-04-5,80416-08-6,80551-63-9,126794-42-1,129947-83-7,131478-70-1,148507-72-6,148507-73-7)

Guidance literature:

Multi-step reaction with 3 steps

1: sodium hydroxide / water / 3 - 5 h / 40 - 45 °C

2: water / 3 h / 0 - 30 °C

3: acetone / 4 h / pH 6.2 / Heating / reflux

With sodium hydroxide; In water; acetone;

upstream raw materials:

(RS)-metoprolol

tartaric acid

4-(2-methoxyethyl)phenol

Downstream raw materials:

3-isopropyl-5-((4-(2-methoxyethyl)phenoxy)methyl)oxazolidin-2-one

C₁₅H₂₄⁽¹²⁵⁾INO₃

N-nitrosometoprolol

Refernces

• 1、 -. "PROCESS FOR MANUFACTURE OF METOPROLOL AND SALTS THEREOF". Page/Page column 9-10. . Retrieved 2008/06/13.
• 2、 -. "Controlled release formulation". . . Retrieved 2008/06/13.